DrugBank ID
stringlengths 7
7
| Accession Numbers
stringlengths 7
102
⌀ | Common name
stringlengths 3
226
| CAS
stringlengths 7
12
⌀ | UNII
stringlengths 10
10
⌀ | Synonyms
stringlengths 2
1.48k
⌀ | Standard InChI Key
stringlengths 27
27
⌀ |
|---|---|---|---|---|---|---|
DB16377
| null |
Tesnatilimab
|
2242758-08-1
|
2B860WP9F0
|
Tesnatilimab
| null |
DB16378
| null |
Tefibazumab
|
521079-87-8
|
SBO7Q9G95R
|
Tefibazumab
| null |
DB16379
| null |
Garetosmab
|
2097125-54-5
|
KR9ZSKO5QE
|
Garetosmab
| null |
DB16380
| null |
Coprelotamab
|
2348469-84-9
|
XQ7509L801
|
Coprelotamab
| null |
DB16381
| null |
Zampilimab
|
2098280-42-1
|
52B38H09GZ
|
Zampilimab
| null |
DB16383
| null |
Bexmarilimab
|
2259301-27-2
|
SA0O2AK3LA
|
Anti-clever-1 monoclonal antibody FP-1305 | Bexmarilimab | Clevegen
| null |
DB16384
| null |
Toralizumab
|
252662-47-8
|
KX44A9HM0B
|
Anti-CD 154 human-mouse monoclonal antibody | Anti-CD40L | Anti-GP39 | Toralizumab
| null |
DB16385
| null |
Ansuvimab
|
2375952-29-5
|
TG8IQ19NG2
|
Ansuvimab | ansuvimab-zykl
| null |
DB16386
| null |
Astegolimab
|
2173054-79-8
|
27TW751DTH
|
Astegolimab
| null |
DB16387
| null |
Levilimab
|
2035008-70-7
|
P7UV3L2H80
|
Levilimab
| null |
DB16388
| null |
Axatilimab
|
2155851-88-8
|
R96Z451BMC
|
anti-Csf1R monoclonal antibody SNDX-6352 | Axatilimab
| null |
DB16389
| null |
Zansecimab
|
2415205-37-5
|
A67ZN01CAW
|
Zansecimab
| null |
DB16390
| null |
Mobocertinib
|
1847461-43-1
|
39HBQ4A67L
|
Mobocertinib
|
AZSRSNUQCUDCGG-UHFFFAOYSA-N
|
DB16391
| null |
Daxdilimab
|
2245966-28-1
|
CNI3N6QR71
|
Daxdilimab
| null |
DB16392
| null |
Avdoralimab
|
2226393-85-5
|
DW4CE8MKS9
|
Avdoralimab
| null |
DB16393
| null |
Cilgavimab
|
2420563-99-9
|
1KUR4BN70F
|
Cilgavimab
| null |
DB16394
| null |
Tixagevimab
|
2420564-02-7
|
F0LZ415Z3B
|
Tixagevimab
| null |
DB16395
| null |
Efineptakin alfa
|
2026634-47-7
|
3K3WC6MT6P
|
Efineptakin alfa | Hyleukin | NT-I7 | Recombinant human IL-7-HYFC | Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (Rhil-7-Hyfc) | Recombinant human interleukin-7 fused to a hybrid crystallizable fragment region of a human antibody (rhIL-7-hyFc). | rhIL-7-hyFc
| null |
DB16396
| null |
Goflikicept
|
2416984-26-2
|
11DRN01OK2
|
Goflikicept | Heterodimeric fusion protein that binds to IL-1 beta consisting of human extracellular domain of IL1 receptor and a mutant Fc fragment of human IGg1 and part of human IL1 receptor accessory protein | RPH-104
| null |
DB16397
| null |
Terevalefim
|
1070881-42-3
|
GG91UXK2M5
|
Refanalin | Terevalefim
|
FOHWAQGURRYJFK-ONEGZZNKSA-N
|
DB16398
| null |
Efmarodocokin alfa
|
1953227-87-6
|
NYZ11835VX
|
Efmarodocokin alfa | HUMAN INTERLEUKIN 22 (1-146), FUSED TO HUMAN IMMUNOGLOBULIN HEAVY CONSTANT GAMMA 4 (CH1(97-98), H(S10>P(158)), CH2(N67>G(227)))-(147-377), DIMER (156-156':159-159')-BISDISULFIDE, PRODUCED IN CHO CELLS, GLYCOFORM ALFA | IL 22-FC | IL-22Fc | INTERLEUKIN 22 (HUMAN (MATURE)) FUSION PROTEIN WITH IMMUNOGLOBULIN G4 (SYNTHETIC HUMAN .GAMMA.4-CHAIN FC REGION (81-GLYCINE)), DIMER
| null |
DB16399
| null |
Modakafusp alfa
| null |
TN8CEX4UT2
|
Anti-CD38-targeted IGG4-attenuated IFNA TAK-573 | Modakafusp alfa
| null |
DB16400
| null |
Sibofimloc
|
1616113-45-1
|
00OF00QZC4
|
Sibofimloc
|
SFHMWDMKUYVSQJ-VECBPBMLSA-N
|
DB16401
| null |
Pidacmeran
|
2417904-10-8
|
6FH8H9CL41
|
Pidacmeran
| null |
DB16402
| null |
BNT-162A1
|
2417899-74-0
|
N38TVC63NU
| null | null |
DB16403
| null |
Isoquercitrin
|
21637-25-2
|
0YX10VRV6J
|
Isoquercetin enzymatically modified | Isoquercitroside | Isotrifoliin | Isotrifolin | Quercetin 3-(beta-D-glucofuranoside)
|
OPJZLUXFQFQYAI-GNPVFZCLSA-N
|
DB16404
| null |
Carvacrol
|
499-75-2
|
9B1J4V995Q
|
5-Isopropyl-o-cresol | p-Cymen-2-ol
|
RECUKUPTGUEGMW-UHFFFAOYSA-N
|
DB16405
| null |
Regdanvimab
|
2444308-95-4
|
I0BGE6P6I6
|
Regdanvimab
| null |
DB16406
| null |
Subasumstat
|
1858276-04-6
|
XQ43H3V6M1
|
Subasumstat
|
LXRZVMYMQHNYJB-UNXOBOICSA-N
|
DB16407
| null |
Azvudine
|
1011529-10-4
|
IJ2XP0ID0K
|
Azvudine
|
KTOLOIKYVCHRJW-XZMZPDFPSA-N
|
DB16408
| null |
Zotatifin
|
2098191-53-6
|
2EWN8Z05CN
|
Zotatifin
|
QYCXWOACFWMQFO-WZWZCULESA-N
|
DB16409
| null |
Tiragolumab
|
1918185-84-8
|
6XG22YQM2Z
|
Tiragolumab
| null |
DB16410
| null |
Datopotamab deruxtecan
|
2238831-60-0
|
GD2OWY1DTK
|
Datopotamab deruxtecan
| null |
DB16411
| null |
Camidanlumab tesirine
|
1853239-04-9
|
LYJ1AEJ9YH
|
Camidanlumab tesirine
| null |
DB16412
| null |
Adebrelimab
|
2247114-85-6
|
1XBY50W1OX
|
Adebrelimab
| null |
DB16413
| null |
Sotigalimab
|
2305607-45-6
|
JEA93WJ5DG
|
CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M | IMMUNOGLOBULIN G1 (270-GLUTAMIC ACID, C-TERMINAL-LYSINE-CLIPPED), ANTI-(HUMAN CD40 ANTIGEN) (HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-ORYCTOLAGUS CUNICULUS MONOCLONAL APX005M .KAPPA.-CHAIN, DIMER | Sotigalimab
| null |
DB16414
| null |
Birtamimab
|
1608108-91-3
|
VXQ2SK8I3P
|
Birtamimab
| null |
DB16415
| null |
Feladilimab
| null |
OUP4QB2A3R
|
Feladilimab
| null |
DB16416
| null |
Vilobelimab
|
2250440-41-4
|
F5T0RF9ZJA
|
IFX-1 | Vilobelimab
| null |
DB16417
| null |
Geptanolimab
|
2348469-43-0
|
FME52R2SGN
|
Genolimzumab | Geptanolimab
| null |
DB16418
| null |
Narsoplimab
|
2108782-45-0
|
FT24ZQQ5RP
|
ANTI-MASP-2 MONOCLONAL ANTIBODY OMS721 | IMMUNOGLOBULIN G4 (226-PROLINE), ANTI-(HUMAN MANNAN-BINDING LECTIN-ASSOCIATED SERINE PROTEASE 2) (HUMAN MONOCLONAL OMS721 .GAMMA.4-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL OMS721 .LAMBDA.-CHAIN, DIMER | IMMUNOGLOBULIN G4-LAMBDA, ANTI-(HOMO SAPIENS MANNAN-BINDING LECTIN SERINE PROTEASE 2 (MANNOSE-BINDING PROTEIN-ASSOCIATED SERINE PROTEASE 2, EC=3.4.21.104) HUMAN MONOCLONAL ANTIBODY .GAMMA.4 HEAVY CHAIN (1-445) (HOMO SAPIENS VH (IGHV2-26*01 (94%) (IGHD)-I | MASP-2 antibody | Narsoplimab
| null |
DB16419
| null |
Ieramilimab
|
2137049-37-5
|
OI8P0SFD4R
|
Ieramilimab
| null |
DB16420
| null |
Vibostolimab
|
2231305-30-7
|
5XO3JF0FEK
|
Vibostolimab
| null |
DB16421
| null |
Volagidemab
|
1233956-13-2
|
77JYS6UZ0M
|
Volagidemab
| null |
DB16422
| null |
Quavonlimab
|
2254059-25-9
|
GG0AN49Y59
|
Quavonlimab
| null |
DB16423
| null |
AK119
| null | null | null | null |
DB16424
| null |
Allocetra
| null | null | null | null |
DB16425
| null |
Rintatolimod
|
38640-92-5
|
94325AJ25N
|
5'-INOSINIC ACID, HOMOPOLYMER, COMPLEX WITH 5'-CYTIDYLIC ACID POLYMER WITH 5'-URIDYLIC ACID (1:1) | Poly I: Poly C12U | POLY(5')-INOSINYL-(3'->) DUPLEX WITH POLY(DODECAKIS(3')-CYTIDYLYL-(5'->)3')-URIDYLYL-(5'->) | Poly(C12U) | Poly(I):poly(C12U) | Rintatolimod
| null |
DB16426
| null |
Sulfur dioxide
|
7446-09-5
|
0UZA3422Q4
|
Schwefeldioxyd | Siarki dwutlenek | Sulfurous oxide | Sulfuroxide
|
RAHZWNYVWXNFOC-UHFFFAOYSA-N
|
DB16427
| null |
VidPrevtyn Beta
| null | null |
COVID-19 Vaccine (recombinant, adjuvanted) | SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
| null |
DB16428
| null |
GRAd-COV2
| null | null | null | null |
DB16429
| null |
CoVac-1
| null | null |
Multi-peptide vaccination | Multipeptide cocktail
| null |
DB16430
| null |
TMV-083
| null | null | null | null |
DB16431
| null |
Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine
| null | null |
RBD SARS-CoV-2 HBsAg VLP vaccine
| null |
DB16432
| null |
MVA-SARS-2-S
| null | null | null | null |
DB16433
| null |
VXA-CoV2-1
| null | null | null | null |
DB16434
| null |
IN01
| null | null | null | null |
DB16435
| null |
AG0302-COVID19
| null |
VX6GTS64AJ
| null | null |
DB16436
| null |
AdimrSC-2f
| null | null | null | null |
DB16437
| null |
V590
| null | null | null | null |
DB16438
| null |
V591
| null | null | null | null |
DB16439
| null |
EpiVacCorona
| null | null | null | null |
DB16440
| null |
Ethyl methoxycinnamate
|
24393-56-4
|
SD418S06XD
|
Ethyl (E)-4-methoxycinnamate | Ethyl (E)-p-methoxycinnamate | Ethyl methoxycinnamate | Ethyl trans-p-methoxycinnamate
|
DHNGCHLFKUPGPX-RMKNXTFCSA-N
|
DB16441
| null |
QazCovid-in
| null | null | null | null |
DB16442
| null |
BNT162b3
| null |
I74C16KK3J
| null | null |
DB16443
| null |
Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)
| null | null | null | null |
DB16444
| null |
UB-612
| null | null |
UB-612 COVID-19 | UB-612 COVID-19 vaccine
| null |
DB16445
| null |
ChulaCov19 mRNA vaccine
| null | null | null | null |
DB16446
| null |
Vafidemstat
|
1357362-02-7
|
LZ82JLT4UP
|
Vafidemstat
|
XBBRLCXCBCZIOI-DLBZAZTESA-N
|
DB16447
| null |
Thymoquinone
|
490-91-5
|
O60IE26NUF
|
2-Isopropyl-5-methyl-p-benzoquinone | p-Cymene-2,5-dione | p-Mentha-3,6-diene-2,5-dione | Thymoquinon
|
KEQHJBNSCLWCAE-UHFFFAOYSA-N
|
DB16448
| null |
Efprezimod alfa
| null |
FN12T66RMN
|
Human CD24 and human IgG Fc Fusion Protein
| null |
DB16449
| null |
Tin protoporphyrin IX
|
14325-05-4
|
DIO3JT9G2P
|
Dihydrogen (OC-6-13)-dichloro[7,12-diethenyl-3,8,13,17-tetramethylporphyrin-2,18-dipropionato(4-)-N<sup>21</sup>,N<sup>22</sup>,N<sup>23</sup>,N<sup>24</sup>]stannate(2-)- | Sn Protoporphyrin | Sn-heme | SnPP | SnPP Protoporphyrin | Stannate(2-), dichloro[7,12-diethenyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)-κ<sup>21</sup>,κN<sup>22</sup>,κN<sup>23</sup>,κN<sup>24</sup>]-, hydrogen (1:2), (OC-6-13)- | Stannic Protoporfin | Tin protoporphyrin IX | TIN, (DIHYDROGEN PROTOPORPHYRIN IX-ATO(2-))-
|
KXYSGXXTXAHPIX-UHEVNVKKSA-J
|
DB16450
| null |
Rexin G
|
1023923-93-4
| null |
DeltaRex-G | DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor | Mx-dnG1 retroviral vector | retroviral expression vector bearing anti-cyclin G1 gene construct | Rexin-G
| null |
DB16451
| null |
AT-527
|
2241337-84-6
|
DAI4WL7JQ6
|
AT527
| null |
DB16452
| null |
MAS825
| null | null | null | null |
DB16453
| null |
Efzofitimod
| null |
V5TNN0W368
|
Human IgG1Fc- iMod domain (amino acids 2-60) of human HARS fusion protein
| null |
DB16454
| null |
XPro1595
|
2489785-77-3
|
BM6T2K8FIN
|
HOMOSAPIENS TUMOR NECROSIS FACTOR,SOLUBLE FORM (V1>M, R31>C, C69>V, Y87>H, C101>A, A145>R), MONOMER, PEGYLATED ON CYSTEINE 31 : S-((3RS)-(2-((3-(.OMEGA.-METHOXYPOLY(OXYETHANE-1,2-DIYL))PROPYL)CARBAMOYL)ETHYL)-2,5-DIOXOPYRROLIDIN-3-YL)-L-CYSTEINYL | NeuLiv | PEGIPANERMIN | Quellor | SOLUBLE TUMOR NECROSIS FACTOR (1-METHIONINE,31-CYSTEINE,69-VALINE,87-HISTIDINE,101-ALANINE,145-ARGININE) (HUMAN CONSTRUCT XPRO1595), 31-THIOETHER WITH .ALPHA.-(3-((3-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOPROPYL)AMINO)PROPYL)-.OMEGA.-METHOXYPOLY(OXY-
| null |
DB16456
| null |
Human Interleukin 8
| null |
PC30892LX5
|
INTERLEUKIN 8 | INTERLEUKIN 8 (HUMAN) | MONOCYTE-DERIVED NEUTROPHIL CHEMOTACTIC FACTOR | NEUTROPHIL-ACTIVATING PROTEIN 1
| null |
DB16457
| null |
Sarconeos
| null | null |
Sarconeos
| null |
DB16458
| null |
Ezurpimtrostat
|
1914148-72-3
|
MS6LGW5JFK
|
Chloroquine analog
|
QVXSJSXAVQJXOV-UHFFFAOYSA-N
|
DB16460
| null |
APL-9
| null | null | null | null |
DB16461
| null |
DFV890
| null | null | null | null |
DB16462
| null |
Veru-111
|
1332881-26-1
|
37L1JX37J5
|
[2-(1H-indol-3-yl)-1H-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone | Methanone, [2-(1H-indol-3-yl)-1H-imidazol-5-yl](3,4,5-trimethoxyphenyl)-
|
WQGVHOVEXMOLOK-UHFFFAOYSA-N
|
DB16463
| null |
TD-0903
|
2412496-23-0
|
CXA4I8AH6A
|
(3-(DIMETHYLAMINO)AZETIDIN-1-YL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-(PROPAN-2-YL)-4,5,6,7-TETRAHYDRO-1H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE | (S)-(3-(DIMETHYLAMINO)AZETIDIN-1-YL)(2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-5-ISOPROPYL-4,5,6,7-TETRAHYDRO-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)METHANONE | METHANONE, (3-(DIMETHYLAMINO)-1-AZETIDINYL)((6S)-2-(6-(2-ETHYL-4-HYDROXYPHENYL)-1H-INDAZOL-3-YL)-4,5,6,7-TETRAHYDRO-5-(1-METHYLETHYL)-3H-IMIDAZO(4,5-C)PYRIDIN-6-YL)- | NEZULCITINIB
|
VQIIUJSNIKEMCK-MHZLTWQESA-N
|
DB16464
| null |
CIGB 300
|
1072877-99-6
|
X6HMT2EDH9
|
P15-Tat
| null |
DB16465
| null |
Meplazumab
| null |
0EL07E29VQ
| null | null |
DB16466
| null |
CM4620
|
1713240-67-5
|
564AW1RR37
|
BENZAMIDE, N-(5-(6-CHLORO-2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)-2-PYRAZINYL)-2-FLUORO-6-METHYL- | N-(5-(6-CHLORO-2,2-DIFLUOROBENZO(D)(1,3)DIOXOL-5-YL)PYRAZIN-2-YL)-2-FLUORO-6-METHYLBENZAMIDE | ZEGOCRACTIN
|
QQMKTHUGOQDEIL-UHFFFAOYSA-N
|
DB16468
| null |
Beta-(1,3)-D glucan
|
9051-97-2
| null |
Adjuvax | beta-1,3-Glucan | GL 32 | Glucan F | Guardoran | Highcareen GS | ImmuStim | PC-3 type glucan | Poly(1-3)-beta-D-glucan | Polysaccharide 13140 | TAK (polysaccharide) | Tak-N | Uniglucan 51 | VitaStim
| null |
DB16469
| null |
Empasiprubart
|
2579031-19-7
|
PVA73UA67L
|
Empasiprubart
| null |
DB16470
| null |
TJ003234
| null |
M1K0A3X96W
| null | null |
DB16471
| null |
TL-895
|
1415823-49-2
| null | null | null |
DB16472
| null |
LSALT Peptide
| null | null |
H-LSALTPSPSWLKYKAL-NH2 | LSALT | Metablok
| null |
DB16473
| null |
MEDI3506
|
2376858-66-9
|
OHZ2MEL7FD
|
Immunoglobulin G1-lambda2, anti-[Homo sapiens IL33 (interleukin 33, DVS27, NF-HEV, IL1F11)], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV3-23*01 (93.9%) -(IGHD) -IGHJ4*01 (85.7%) L123>M (121)) CDR-IMGT [8.8.19] (26-33.51-58.97-1 | Immunoglobulin G1, anti-(human interleukin 33) (human monoclonal MEDI3506 γ1-chain), disulfide with human monoclonal MEDI3506 λ-chain, dimer | TOZORAKIMAB
| null |
DB16474
| null |
Pam2csk4
|
574741-81-4
|
L33ZW7BO91
|
Pam2 | Pam2CSK4 | Pam2CSK4 acetate
|
LJUIOEFZFQRWJG-KKIBDXJDSA-N
|
DB16475
| null |
STC3141
| null | null | null | null |
DB16476
| null |
Carrimycin
| null |
K5E0V85NB9
|
4''-Isovalerylspiramycin | Carrimycin
| null |
DB16477
| null |
EB05
|
2641646-59-3
|
4LH8QAS0LR
|
Immunoglobulin G1 [326-serine,329-phenylalanine,de-448-lysine], anti-(human Toll-like receptor 4) (human-Mus musculus monoclonal EB05 γ1-chain), disulfide with human-Mus musculus monoclonal EB05 κ-chain, dimer | Paridiprubart
| null |
DB16479
| null |
Inbakicept
|
2135939-52-3
|
QN4LI58PJ5
|
ALT-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN | Inbakicept | INTERLEUKIN 15 RECEPTOR .ALPHA. CHAIN (HUMAN SUSHI DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN FC FRAGMENT), DIMER | INTERLEUKIN 15 RECEPTOR SUBUNIT ALPHA (HUMAN IL15R.ALPHA.) (1-65)-PEPTIDE (SUSHI DOMAIN-CONTAINING) FUSION PROTEIN WITH HUMAN IMMUNOGLOBULIN G1 FC FRAGMENT (232 C-TERMINAL RESIDUES) (66-297) (HOMO SAPIENS IGHG1*01, HINGE (71-80), CH2 (81-190), CH3 (191-2 | N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN
| null |
DB16480
| null |
BDB-001
| null | null |
BDB 001 | BDB001
| null |
DB16481
| null |
Dociparstat sodium
|
177021-00-0
|
4O75889WF4
|
2,3-o-Desulfated heparin (12000 da) | Dociparstat sodium
| null |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.